Latest News
-
-
Volastra unveils first human data of its solid tumor drug target
Companies To Watch: Volastra Therapeutics
Volastra vies for the next big synthetic lethality target
Volastra Therapeutics Forms New Partnerships to Advance KIF18A Inhibitors in Cancer
Targeting A Multitude of CIN in Cancer Cells (Podcast)
Lilly-Backed Volastra Enters Clinic with Amgen’s KIF18A Inhibitor
Volastra licenses Amgen molecule for chromosomally unstable cancers
Armed with $60M series A and Lilly’s backing, Volastra enters clinic via Amgen cancer med
Oncology specialist Volastra brings in PhI drug from Amgen, nabs $60M in Series A
On heels of landmark approval, Bristol Myers Squibb embarks on billion-dollar oncology deal with metastatic cancer startup
Bristol Myers lands $1.1B biobucks oncology pact with Volastra, a biotech with phones ‘ringing off the hook’
Volastra, Microsoft team up to battle cancer
With fresh investor cash in hand, Volastra partners with Microsoft to develop metastatic cancer biomarker platform
Volastra bumps up seed round to $44M, inks Microsoft partnership to tackle cancer metastasis
Volastra’s Strong Year Continues with Microsoft Deal and Extended Seed Financing
Volastra Therapeutics has now raised $44M, partners with Microsoft
Why this early-stage drug-discovery firm chose to grow in New York City
Volastra Therapeutics Names First CEO
Agios’ Lewis Cantley returns with a new company and, he claims, a major oncological discovery
